You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 1, 2024

Blueprint Medicines Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for BLUEPRINT MEDICINES, and what generic alternatives to BLUEPRINT MEDICINES drugs are available?

BLUEPRINT MEDICINES has two approved drugs.

There are seven US patents protecting BLUEPRINT MEDICINES drugs.

There are ninety-seven patent family members on BLUEPRINT MEDICINES drugs in forty countries and sixteen supplementary protection certificates in fourteen countries.

Summary for Blueprint Medicines
International Patents:97
US Patents:7
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Blueprint Medicines

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-005 Jun 16, 2021 RX Yes No ⤷  Try a Trial ⤷  Try a Trial
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-005 Jun 16, 2021 RX Yes No ⤷  Try a Trial ⤷  Try a Trial
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-002 Jan 9, 2020 RX Yes No ⤷  Try a Trial ⤷  Try a Trial
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-001 Jan 9, 2020 RX Yes No ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Blueprint Medicines Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3057969 21C1013 France ⤷  Try a Trial PRODUCT NAME: AVAPRITINIB ET LES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/20/1473 20200925; FIRST REGISTRATION: - EU/1/20/1473 20200925
3057969 SPC/GB21/020 United Kingdom ⤷  Try a Trial PRODUCT NAME: AVAPRITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK PLGB52115/0001-0003 20200925; UK EU/1/20/1473(NI) 20200925
3057969 C03057969/01 Switzerland ⤷  Try a Trial PRODUCT NAME: AVAPRITINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68294 06.07.2023
3057969 10/2021 Austria ⤷  Try a Trial PRODUCT NAME: AVAPRITINIB UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/20/1473 (MITTEILUNG) 20200925
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.